Vertex Pharmaceuticals (VRTX) R&D In Process (2021 - 2025)
Historic R&D In Process for Vertex Pharmaceuticals (VRTX) over the last 5 years, with Q4 2025 value amounting to $56.5 million.
- Vertex Pharmaceuticals' R&D In Process fell 3542.86% to $56.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $133.0 million, marking a year-over-year decrease of 9712.64%. This contributed to the annual value of $133.0 million for FY2025, which is 9712.64% down from last year.
- Latest data reveals that Vertex Pharmaceuticals reported R&D In Process of $56.5 million as of Q4 2025, which was down 3542.86% from $54.5 million recorded in Q3 2025.
- Vertex Pharmaceuticals' 5-year R&D In Process high stood at $4.4 billion for Q2 2024, and its period low was $2.0 million during Q1 2022.
- In the last 5 years, Vertex Pharmaceuticals' R&D In Process had a median value of $54.5 million in 2025 and averaged $342.9 million.
- Per our database at Business Quant, Vertex Pharmaceuticals' R&D In Process surged by 1725500.0% in 2023 and then plummeted by 9995.06% in 2025.
- Quarter analysis of 5 years shows Vertex Pharmaceuticals' R&D In Process stood at $126.5 million in 2021, then tumbled by 82.13% to $22.6 million in 2022, then decreased by 21.24% to $17.8 million in 2023, then surged by 391.57% to $87.5 million in 2024, then crashed by 35.43% to $56.5 million in 2025.
- Its last three reported values are $56.5 million in Q4 2025, $54.5 million for Q3 2025, and $2.2 million during Q2 2025.